The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
High-Dose Cisplatin in Hypertonic Saline
Abstract
To overcome the dose limiting toxicity of cisplatin we have administered high-dose cisplatin (200 mg/m2 body surface area in five divided daily doses with each dose administered in 250 mL of 3% saline) together with extensive hydration (250 mL/h normal saline with 20 meq KCI/L). In 17 previously untreated patients with poor prognosis nonseminomatous testicular cancer, 8 with tumor-associated obstructive uropathy, there was no statistically significant decrease in creatinine clearance or elevation of serum creatinine after three to four cycles of a high-dose cisplatin in combination chemotherapy regimen. High-dose cisplatin in combination with vinblastine, bleomycin, and VP-16 produced an 88% complete response rate in these high-risk patients who are characterized primarily by the presence of advanced bulky lung and abdominal disease. Six patients with ovarian cancer who had a relapse after treatment with standard dose cisplatin regimens were treated with high-dose cisplatin and three partial responses were seen. Four patients had no adverse effects on renal function whereas 2 patients had transient elevations in serum creatinine (4 to 5 mg/dL). Hypertonic saline did not provide protection against the nonrenal toxicities of cisplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresis
Hayes, D. M., Cvitkovic, E., Golbey, R. B., Scheiner, E., Helson, L., & Krakoff, I. H. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j · Cited by 626
Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells
Eva, A., Robbins, K. C., Andersen, P. R., Srinivasan, A., Tronick, S. R., Reddy, E. P., Ellmore, N. W., Galen, A. T., Lautenberger, J. A., Papas, T. S., et al. (1982) · Nature · doi:10.1038/295116a0 · Cited by 497
Intraperitoneal Cisplatin with Systemic Thiosulfate Protection
HOWELL, S. B., PFEIFLE, C. L., WUNG, W. E., OLSHEN, R. A., LUCAS, W. E., YON, J. L., & GREEN, M. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-6-845 · Cited by 485
Stoter, G., Sleijfer, D. T., Vendrik, C. P. J., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91719-7 · Cited by 97
Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites.
Ozols, R. F., Willson, J. K. V., Weltz, M. D., Grotzinger, K. R., Myers, C. E., & Young, R. C. (1980) · PubMed · Cited by 88
Self-citationBarker, G. H., & Wiltshaw, E. (1981) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1981.tb01196.x · Cited by 64
Cited by
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
LOEHRER, P. J., & EINHORN, L. H. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-5-704 · Cited by 947
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358
Anticancer Drug???Induced Kidney Disorders: Incidence, Prevention and Management
Kintzel, P. E. (2001) · Drug Safety · doi:10.2165/00002018-200124010-00003 · Cited by 355
Metadata
- Authors
- OZOLS, R. F., CORDEN, B. J., JACOB, J., WESLEY, M. N., OSTCHEGA, Y., & YOUNG, R. C.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1984-01-01
- Volume
- 100
- Issue
- 1
- Pages
- 19-24
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2032528970
- Cited by
- 333
- References
- 7
- FWCI
- 29.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-Dose Cisplatin in Hypertonic Saline. https://app.cochat.ai/papers/10.7326/0003-4819-100-1-19
- The paper
- OZOLS, R. F., CORDEN, B. J., JACOB, J., WESLEY, M. N., OSTCHEGA, Y., & YOUNG, R. C. (1984). High-Dose Cisplatin in Hypertonic Saline. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-100-1-19
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.